
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is well-positioned for success in the biotechnology industry due to its strong pipeline of precision oncology therapies, with vopimetostat and TNG456 showing promising results in clinical trials. The company's partnerships with RevMed and ERAS-0015 also demonstrate the potential for collaboration and continue innovation in the field. While there are risks associated with clinical trials and obtaining regulatory approvals, Tango Therapeutics has a strong investment value, with a DCF-based valuation estimating a 12-month price objective of $68 per share. Upcoming catalysts, such as data updates and initiations of pivotal trials, further support a positive outlook for the future of the company.
Bears say
Tango Therapeutics is facing intense competition in the biotechnology industry, particularly in the field of precision oncology therapies for the treatment of cancer. The company's pipeline products, PRMT5 and CoREST, face potential delays in FDA approval as well as significant competition from other PRMT5 drugs, particularly in the Chinese market. Additionally, potential safety concerns and slower than anticipated physician uptake could limit the company's revenues and pose downside risk to the stock and price target. With the highly competitive nature of the oncology market and potential challenges in FDA approval and market adoption, this financial analyst holds a negative outlook on Tango Therapeutics's stock performance.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares